Media coverage of the FDA-approved Alzheimer's drug aducanumab made the public less willing to volunteer in Alzheimer's pharmaceutical trials.
Aduhelm, a new drug that appears to reduce amyloid plaques in the brain, is the first new Alzheimer's disease medication to be approved since 2003, and is the first drug that targets the fundamental pathology of the disease.
A newly developed antibody has shown to trigger a meaningful reduction of amyloid beta in patients with early stage Alzheimer's disease.
